Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,815 result(s) found for: Chemotherapy. Displaying page 141 of 291.
    «« First « Previous 137  138  139  140  141  142  143  144  145  Next» Last»»
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005725-29 Sponsor Protocol Number: EGF110656 Start Date*: 2008-05-09
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib
    Medical condition: Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) IT (Completed) NL (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004190-13 Sponsor Protocol Number: TX05-03 Start Date*: 2018-02-08
    Sponsor Name:Tanvex Biologics Corp.
    Full Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer
    Medical condition: HER-2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001164-30 Sponsor Protocol Number: TAS-120-201 Start Date*: 2019-11-22
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
    Medical condition: Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002509-21 Sponsor Protocol Number: FIL-Rouge Start Date*: 2017-07-17
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response...
    Medical condition: Advanced stage (IIB-IV) Hodgkin Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002284-18 Sponsor Protocol Number: UC-0140/1711 Start Date*: 2017-12-02
    Sponsor Name:UNICANCER
    Full Title: A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine
    Medical condition: Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally advanced (unresectable) or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004181-20 Sponsor Protocol Number: IEO1360 Start Date*: 2021-09-22
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Camidanlumab tesirine (ADCT-301) in older classical Hodgkin lymphoma (cHL) patients with relapsed or refractory disease after front-line treatment or at high risk of failure, defined by a positive ...
    Medical condition: Relapsed or refractory Hodgkin's lymphoma after first-line chemotherapy or at high risk of failure, as defined by persistence of PET-positivity after the first two courses of first-line chemotherap...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020234 Hodgkin's disease mixed cellularity refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020233 Hodgkin's disease mixed cellularity recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000276-15 Sponsor Protocol Number: OV-AP-ICG-IV Start Date*: 2013-03-08
    Sponsor Name:Jules Bordet Institute
    Full Title: Feasibility study of the (intravenously injected) Indocyanine green (ICG) imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma
    Medical condition: Peritoneal carcinomatosis from ovarian cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000559-15 Sponsor Protocol Number: FB2012 Start Date*: 2012-09-14
    Sponsor Name:FinnBladder
    Full Title: TREATMENT OF Ta BLADDER CANCER WITH HIGH RISK OF RECURRENCE – FLUORESCENCE CYSTOSCOPY WITH OPTIMIZED ADJUVANT MITOMYCIN-C
    Medical condition: bladder cancer (non-invasive Ta urothelial bladder cancer)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-020472-34 Sponsor Protocol Number: IEO S542/310 Start Date*: 2010-12-14
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: 18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma
    Medical condition: Breast carcinoma classified as cT1b,c, T2, T3, or cT4 a-c, cN0-2, N3, M0
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006289 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002971-42 Sponsor Protocol Number: PEG-HSR Start Date*: 2006-06-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.
    Medical condition: patients affected by linphoproliferative pathologies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001532-11 Sponsor Protocol Number: 01apr2014 Start Date*: 2014-09-11
    Sponsor Name:Ospedale San Raffaele
    Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE...
    Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000169-14 Sponsor Protocol Number: INES Start Date*: 2023-05-03
    Sponsor Name:Fondazione Santobono Pausilipon ONLUS
    Full Title: Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma
    Medical condition: Ewing Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004675-31 Sponsor Protocol Number: AMCmedonc17-010 Start Date*: 2019-11-13
    Sponsor Name:Academic Medical Center
    Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs...
    Medical condition: pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001777-19 Sponsor Protocol Number: HOVON 81 AML Start Date*: 2006-12-07
    Sponsor Name:HOVON foundation
    Full Title: A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
    Medical condition: Acute myeloid leukaemia (AML), AML FAB M0-M2 or M4-M7; diagnosis with refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-T) with an IP...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000653-42 Sponsor Protocol Number: OC-AP-ICG-IV Start Date*: 2013-03-20
    Sponsor Name:Jules Bordet Institute
    Full Title: Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from colorectal cancer
    Medical condition: Peritoneal carcinomatosis from colon Cancer.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005050-20 Sponsor Protocol Number: NURE-Combo Start Date*: 2021-10-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: An open label, single-arm, phase 2 study od neoadjuvant nivolumab and nab-paclitaxel before cystectomy for patients with muscle-invasive bladder cancer
    Medical condition: muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000035-50 Sponsor Protocol Number: ACT16146 Start Date*: 2020-08-07
    Sponsor Name:Sanofi aventis recherche & développement
    Full Title: Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non–small-cell lu...
    Medical condition: Non-squamous non–small-cell lung cancer (NSQ NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001103-21 Sponsor Protocol Number: ONC-MANILA12 Start Date*: 2012-12-05
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: MANTAINANCE METRONOMIC PER OS NAVELBINE IN ADVANCED NSCLC PATIENTS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: A MULTICENTER RANDOMIZED BEST SUPPORTIVE CARE CONTROLLED PHASE II STUDY: MA.NI.LA. TRIAL.
    Medical condition: Advanced non small cell lung cancer (NSCLC) (Inoperable Stage III - IV).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004853-26 Sponsor Protocol Number: T315/2018 Start Date*: 2019-03-25
    Sponsor Name:Turku University Hospital
    Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 137  138  139  140  141  142  143  144  145  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 03:09:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA